NasdaqGS:ADPTLife Sciences
Why Adaptive Biotechnologies (ADPT) Is Down 13.8% After 2025 Results And MRD-Focused 2026 Outlook – And What's Next
In early February 2026, Adaptive Biotechnologies reported full-year 2025 results showing revenue of US$276.98 million and a reduced net loss of US$59.5 million, alongside lower basic loss per share from continuing operations of US$0.39.
The company also issued 2026 guidance for its measurable residual disease (MRD) business, projecting full-year revenue of US$255 million to US$265 million while withholding guidance for its Immune Medicine segment, highlighting a sharper focus on this key...